The KEAP1–NRF2 pathway has been a focal point of extensive research, previously aimed at assessing its potential involvement in chronic human diseases characterized by disruptions in redox balance, including conditions such as diabetes, cardiovascular disease, neurodegenerative diseases, and cancer. The gene discussed is NFE2L2; the disease is neurodegenerative disease.